US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary

R. Andres Floto; Kenneth N. Olivier; Lisa Saiman; Charles L. Daley; Jean Louis Herrmann; Jerry A. Nick; Peadar G. Noone; Diana Bilton; Paul Corris; Ronald L. Gibson; Sarah E. Hempstead; Karsten Koetz; Kathryn A. Sabadosa; Isabelle Sermet-Gaudelus; Alan R. Smyth; Jakko Van Ingen; Richard J. Wallace; Kevin L. Winthrop; Bruce C. Marshall; Charles S. Haworth

doi:10.1136/thoraxjnl-2015-207983

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary

R. Andres Floto^*, Kenneth N. Olivier, Lisa Saiman, Charles L. Daley, Jean Louis Herrmann, Jerry A. Nick, Peadar G. Noone, Diana Bilton, Paul Corris, Ronald L. Gibson, Sarah E. Hempstead, Karsten Koetz, Kathryn A. Sabadosa, Isabelle Sermet-Gaudelus, Alan R. Smyth, Jakko Van Ingen, Richard J. Wallace, Kevin L. Winthrop, Bruce C. Marshall, Charles S. Haworth

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

376 Citations (Scopus)

23 Downloads (Pure)

Abstract

Non-tuberculous mycobacteria (NTM) are ubiquitous environmental organisms that can cause chronic pulmonary infection, particularly in individuals with pre-existing inflammatory lung disease, such as cystic fibrosis (CF). Pulmonary disease (PD) caused by NTM has emerged as a major threat to the health of individuals with CF, but remains difficult to diagnose and problematic to treat. In response to this challenge, the US Cystic Fibrosis Foundation (CFF) and the European Cystic Fibrosis Society (ECFS) convened a panel of 19 experts to develop consensus recommendations for the screening, investigation, diagnosis and management of NTM-PD in individuals with CF. PICO ( population, intervention, comparison, outcome) methodology and systematic literature reviews were employed to inform draft recommendations, which were then modified to achieve consensus and subsequently circulated for public consultation within the USA and European CF communities. We have thus generated a series of pragmatic, evidence-based recommendations as an initial step in optimising management for this challenging condition.

Original language	English
Pages (from-to)	88-90
Number of pages	3
Journal	Thorax
Volume	71
Issue number	1
Early online date	16 Dec 2015
DOIs	https://doi.org/10.1136/thoraxjnl-2015-207983
Publication status	Published - 01 Jan 2016
Externally published	Yes

Bibliographical note

Funding Information:
Cystic Fibrosis Foundation; European Cystic Fibrosis Society, The Wellcome Trust and Cambridge NIHR BRC (RAF); Intramural programme of the National Heart, Lung, and Blood Institute, NIH (KNO); Vaincre La Mucoviscidose (VLMIC1014 and RF20120600689) and the RéAgion Ile-de-France Domaine d’Intérêt Majeur Maladies Infectieuses et Emergentes ( J-LH); CF Foundation Clinical Research Award (NICK13A0) ( JAN) and Imperial College London NIHR Respiratory BRU (DB).

Publisher Copyright:
© 2015, BMJ Publishing Group. All rights reserved.

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.1136/thoraxjnl-2015-207983Licence: CC BY

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary
Copyright 2015 the authors. This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
Final published version, 1.34 MBLicence: CC BY

Cite this

Floto, R. A., Olivier, K. N., Saiman, L., Daley, C. L., Herrmann, J. L., Nick, J. A., Noone, P. G., Bilton, D., Corris, P., Gibson, R. L., Hempstead, S. E., Koetz, K., Sabadosa, K. A., Sermet-Gaudelus, I., Smyth, A. R., Van Ingen, J., Wallace, R. J., Winthrop, K. L., Marshall, B. C., & Haworth, C. S. (2016). US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary. Thorax, 71(1), 88-90. https://doi.org/10.1136/thoraxjnl-2015-207983

@article{95713933bbab44e78e6276e15ef59ea6,

title = "US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary",

abstract = "Non-tuberculous mycobacteria (NTM) are ubiquitous environmental organisms that can cause chronic pulmonary infection, particularly in individuals with pre-existing inflammatory lung disease, such as cystic fibrosis (CF). Pulmonary disease (PD) caused by NTM has emerged as a major threat to the health of individuals with CF, but remains difficult to diagnose and problematic to treat. In response to this challenge, the US Cystic Fibrosis Foundation (CFF) and the European Cystic Fibrosis Society (ECFS) convened a panel of 19 experts to develop consensus recommendations for the screening, investigation, diagnosis and management of NTM-PD in individuals with CF. PICO ( population, intervention, comparison, outcome) methodology and systematic literature reviews were employed to inform draft recommendations, which were then modified to achieve consensus and subsequently circulated for public consultation within the USA and European CF communities. We have thus generated a series of pragmatic, evidence-based recommendations as an initial step in optimising management for this challenging condition.",

author = "Floto, {R. Andres} and Olivier, {Kenneth N.} and Lisa Saiman and Daley, {Charles L.} and Herrmann, {Jean Louis} and Nick, {Jerry A.} and Noone, {Peadar G.} and Diana Bilton and Paul Corris and Gibson, {Ronald L.} and Hempstead, {Sarah E.} and Karsten Koetz and Sabadosa, {Kathryn A.} and Isabelle Sermet-Gaudelus and Smyth, {Alan R.} and {Van Ingen}, Jakko and Wallace, {Richard J.} and Winthrop, {Kevin L.} and Marshall, {Bruce C.} and Haworth, {Charles S.}",

note = "Funding Information: Cystic Fibrosis Foundation; European Cystic Fibrosis Society, The Wellcome Trust and Cambridge NIHR BRC (RAF); Intramural programme of the National Heart, Lung, and Blood Institute, NIH (KNO); Vaincre La Mucoviscidose (VLMIC1014 and RF20120600689) and the R{\'e}Agion Ile-de-France Domaine d{\textquoteright}Int{\'e}r{\^e}t Majeur Maladies Infectieuses et Emergentes ( J-LH); CF Foundation Clinical Research Award (NICK13A0) ( JAN) and Imperial College London NIHR Respiratory BRU (DB). Publisher Copyright: {\textcopyright} 2015, BMJ Publishing Group. All rights reserved.",

year = "2016",

month = jan,

day = "1",

doi = "10.1136/thoraxjnl-2015-207983",

language = "English",

volume = "71",

pages = "88--90",

journal = "Thorax",

issn = "0040-6376",

publisher = "BMJ Publishing Group",

number = "1",

}

Floto, RA, Olivier, KN, Saiman, L, Daley, CL, Herrmann, JL, Nick, JA, Noone, PG, Bilton, D, Corris, P, Gibson, RL, Hempstead, SE, Koetz, K, Sabadosa, KA, Sermet-Gaudelus, I, Smyth, AR, Van Ingen, J, Wallace, RJ, Winthrop, KL, Marshall, BC & Haworth, CS 2016, 'US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary', Thorax, vol. 71, no. 1, pp. 88-90. https://doi.org/10.1136/thoraxjnl-2015-207983

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary. / Floto, R. Andres; Olivier, Kenneth N.; Saiman, Lisa et al.
In: Thorax, Vol. 71, No. 1, 01.01.2016, p. 88-90.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary

AU - Floto, R. Andres

AU - Olivier, Kenneth N.

AU - Saiman, Lisa

AU - Daley, Charles L.

AU - Herrmann, Jean Louis

AU - Nick, Jerry A.

AU - Noone, Peadar G.

AU - Bilton, Diana

AU - Corris, Paul

AU - Gibson, Ronald L.

AU - Hempstead, Sarah E.

AU - Koetz, Karsten

AU - Sabadosa, Kathryn A.

AU - Sermet-Gaudelus, Isabelle

AU - Smyth, Alan R.

AU - Van Ingen, Jakko

AU - Wallace, Richard J.

AU - Winthrop, Kevin L.

AU - Marshall, Bruce C.

AU - Haworth, Charles S.

N1 - Funding Information: Cystic Fibrosis Foundation; European Cystic Fibrosis Society, The Wellcome Trust and Cambridge NIHR BRC (RAF); Intramural programme of the National Heart, Lung, and Blood Institute, NIH (KNO); Vaincre La Mucoviscidose (VLMIC1014 and RF20120600689) and the RéAgion Ile-de-France Domaine d’Intérêt Majeur Maladies Infectieuses et Emergentes ( J-LH); CF Foundation Clinical Research Award (NICK13A0) ( JAN) and Imperial College London NIHR Respiratory BRU (DB). Publisher Copyright: © 2015, BMJ Publishing Group. All rights reserved.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Non-tuberculous mycobacteria (NTM) are ubiquitous environmental organisms that can cause chronic pulmonary infection, particularly in individuals with pre-existing inflammatory lung disease, such as cystic fibrosis (CF). Pulmonary disease (PD) caused by NTM has emerged as a major threat to the health of individuals with CF, but remains difficult to diagnose and problematic to treat. In response to this challenge, the US Cystic Fibrosis Foundation (CFF) and the European Cystic Fibrosis Society (ECFS) convened a panel of 19 experts to develop consensus recommendations for the screening, investigation, diagnosis and management of NTM-PD in individuals with CF. PICO ( population, intervention, comparison, outcome) methodology and systematic literature reviews were employed to inform draft recommendations, which were then modified to achieve consensus and subsequently circulated for public consultation within the USA and European CF communities. We have thus generated a series of pragmatic, evidence-based recommendations as an initial step in optimising management for this challenging condition.

AB - Non-tuberculous mycobacteria (NTM) are ubiquitous environmental organisms that can cause chronic pulmonary infection, particularly in individuals with pre-existing inflammatory lung disease, such as cystic fibrosis (CF). Pulmonary disease (PD) caused by NTM has emerged as a major threat to the health of individuals with CF, but remains difficult to diagnose and problematic to treat. In response to this challenge, the US Cystic Fibrosis Foundation (CFF) and the European Cystic Fibrosis Society (ECFS) convened a panel of 19 experts to develop consensus recommendations for the screening, investigation, diagnosis and management of NTM-PD in individuals with CF. PICO ( population, intervention, comparison, outcome) methodology and systematic literature reviews were employed to inform draft recommendations, which were then modified to achieve consensus and subsequently circulated for public consultation within the USA and European CF communities. We have thus generated a series of pragmatic, evidence-based recommendations as an initial step in optimising management for this challenging condition.

U2 - 10.1136/thoraxjnl-2015-207983

DO - 10.1136/thoraxjnl-2015-207983

M3 - Article

C2 - 26678435

AN - SCOPUS:84958211439

SN - 0040-6376

VL - 71

SP - 88

EP - 90

JO - Thorax

JF - Thorax

IS - 1

ER -

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary

Abstract

Bibliographical note

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this